Home › Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy
 

Keywords :   


Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy

2015-12-02 02:15:49| drugdiscoveryonline Home Page

Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, recently announced a collaboration to explore the potential utility of daily physiological activity monitoring in boys affected by Duchenne muscular dystrophy (DMD) with ActiGraph, a leading provider of objective physical activity and sleep/wake measurement solutions for the global scientific community

Tags: with daily activity trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.06Tnemec Elevates Coatings Education with Newly Appointed AMPP CIP Instructor
18.06Next MANAchat Series is Scheduled for the Week of August 5
18.06Ruben Harris joins Flexcon as VP of supply chain
18.06Joanna Gaines, KILZ Debut Magnolia Lakehouse Collection
18.06Advanced Polymer Coatings Launches TriFLEX for Rail Cars
18.06Potential Tropical Cyclone One Graphics
18.06Potential Tropical Cyclone One Forecast Discussion Number 4
18.06Potential Tropical Cyclone One Forecast Advisory Number 4
More »